Live Breaking News & Updates on Horizon therapeutics public limited company stock exchange

Stay updated with breaking news from Horizon therapeutics public limited company stock exchange. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Horizon Therapeutics plc Announces Data from the TEPEZZA® (teprotumumab-trbw) Phase 4 Clinical Trial in Patients with Chronic/Low CAS Thyroid Eye Disease (TED) to be Presented at the Upcoming Endocrine Society (ENDO) Annual Meeting

-- TEPEZZA Phase 4 trial results to be shared in an oral presentation on Saturday, June 17 at 3:30 p.m. CT --

-- Two patients will share their real-world experience living with TED and being... | June 5, 2023

Olmsted-county , Minnesota , United-states , Chicago , Illinois , Jeffreyw-sherman , Malini-gupta , Instagram , Duke-university-health-system , European-group-on-grave-orbitopathy , Nasdaq , Linkedin

Biomarker Analysis Publication Highlights Key Signals of Disability Worsening Associated With Neuromyelitis Optica Spectrum Disorder (NMOSD) Attacks, Illustrates Efficacy of UPLIZNA® (inebilizumab-cdon)

-- Analysis in The Journal of Neurology, Neurosurgery and Psychiatry demonstrate the direct effect of UPLIZNA on levels of sNFL and sGFAP, two key biomarkers strongly associated with NMOSD attacks... | June 1, 2023

United-states , Germany , Neuroimmunol-neuroinflamm , Orhan-aktas , Kristina-patterson , Instagram , Linkedin , Department-of-neurology , Twitter , Nasdaq , Exchange-commission , Facebook

Presentations at the 2023 EULAR European Congress of Rheumatology Highlight New Results from Phase 2 Trial Evaluating Dazodalibep in Sjögren's Syndrome

-- Only Sjögren’s syndrome Phase 2 trial to meet the primary endpoint in both patient population types --

-- Patients with moderate-to-severe systemic disease activity treated with... | May 31, 2023

Milan , Lombardia , Italy , South-hall , Argyll-and-bute , United-kingdom , Elizabethhz-thompson , Linkedin , Newcastle-university , Facebook , European-congress

Horizon Therapeutics plc Announces Presentation of Data that Advances the Understanding of Rheumatic Diseases at the 2023 EULAR European Congress of Rheumatology

-- Phase 2 results for dazodalibep in Sjögren’s syndrome to be presented on June 1, 11:35-11:45 a.m. CEST and June 3, 9:35-9:45 a.m. CEST --

-- Planned presentations illustrate... | May 23, 2023

South-hall , Argyll-and-bute , United-kingdom , Milan , Lombardia , Italy , Chiara-baldini , Elizabethhz-thompson , Department-of-clinical , Clinical-research-institute , University-of-pisa , Newcastle-university

Horizon Therapeutics plc Responds to U.S. Federal Trade Commission (FTC) Action to Block Acquisition by Amgen

Horizon Therapeutics plc today issued the following statement in response to the FTC’s complaint seeking to block Amgen’s proposed acquisition of the Company:

“This acquisition... | May 16, 2023

Linkedin , Instagram , Nasdaq , Twitter , Facebook , Amgen , Horizon-therapeutics , Horizon-therapeutics-public-limited-company-stock-exchange , News , Nformation , Ress-release

Horizon Therapeutics plc ("Horizon") - Rule 2.12 Announcement

In accordance with Rule 2.12 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022 , Horizon confirms that, as of the close of business on March 31, 2023, Horizon’s issued ordinary share... | May 4, 2023

Ireland , Irish , Irish-takeover-panel , International-securities-identification-number , Irish-takeover-panel-act , Takeover-rules , Ordinary-shares , Nasdaq-global-select-market , Irish-takeover , Irish-takeover-rules , Horizon-therapeutics-public-limited-company-stock-exchange

Horizon Therapeutics plc Reports First-Quarter 2023 Financial Results

First-Quarter 2023 Results:
-- Net Sales of $832.1 Million --
-- GAAP Net Income of $54.7 Million; Adjusted EBITDA of $232.9 Million --
-- TEPEZZA® Net Sales of $405.3 Million --
--... | May 3, 2023

Ireland , Japan , Ukraine , United-states , Russia , Tim-walbert , Viela-bio-inc , Companies-to-work , Nasdaq , Top-biotechnology-pharmaceutical-company , Facebook , Clinical-program-expected-to

Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Lupus Nephritis

Horizon Therapeutics plc today announced the first patient has enrolled in a Phase 2 randomized placebo-controlled trial to evaluate its development-stage medicine daxdilimab, a potentially... | May 2, 2023

San-diego , California , United-states , American , Theresa-podrebarac , Kenneth-kalunian , Drug-administration , Nasdaq , Instagram , Facebook , University-of-california , Twitter

Horizon Therapeutics plc Announces Initiation of Phase 3 Clinical Trial in Japan Evaluating TEPEZZA® (teprotumumab-trbw) in Adults with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)

Horizon Therapeutics plc today announced that the first patient has been enrolled in a Phase 3 clinical trial in Japan evaluating TEPEZZA for the treatment of adults with chronic Thyroid Eye Disease... | May 1, 2023

United-states , Japan , Elizabethhz-thompson , Twitter , Nasdaq , Instagram , Drug-administration , Devices-agency , Visa , Japan-pharmaceuticals , Facebook

Horizon Therapeutics plc Announces UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be Presented at the 2023 American Academy of Neurology (AAN) Annual Meeting

-- Oral presentation on the relationship between B-cell subsets and NMOSD attacks to be held on April 23 at 1:48 p.m. EDT --

... | April 20, 2023

United-states , Boston , Massachusetts , American , Neuroimmunol-neuroinflamm , Neuromyelitis-optica , Mandeep-kaur , Nasdaq , American-academy-of-neurology , Facebook , Instagram , Linkedin